Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An update from Seres Therapeutics ( (MCRB) ) is now available.
Seres Therapeutics has finalized the sale of its VOWST business to Nestlé Health Science, enhancing its financial standing and honing its focus on developing live biotherapeutics for patients at high risk of severe bacterial infections. The deal includes an immediate cash payment and potential future milestone payments, based on VOWST’s net sales, totaling up to $275 million. Additionally, Seres will provide transition services to facilitate the business handover, while retaining a non-exclusive license to certain intellectual property. The agreement also involves SPN’s purchase of Seres’ common stock and an employee support arrangement to ensure a smooth transition.
See more data about MCRB stock on TipRanks’ Stock Analysis page.
